Therapeutic Focus

Filter by:

RZ358
RZ402
Show All

RZ358 Publications

$Treatment-Of-Severe-Refractory-Hypoglycemia-Due-To-Malignant-Insulinoma-With-A-Novel-Anti-Insulin-Receptor-Antibody-thumb$

Treatment Of Severe Refractory Hypoglycemia Due To Malignant Insulinoma With A Novel Anti-Insulin Receptor Antibody

RIZE Study results thumbnail

Phase 2b RIZE Data Presentation by Hüseyin Demirbilek, M.D. at ESPE 2022

Continuous-Glucose-Monitoring-(CGM)-Reveals-Undertreated-Hypoglycemia-in-Patients-with-Congenital-Hyperinsulinism-thumb

Continuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital Hyperinsulinism

Single-Dose-Studies-of-RZ358-in-Patients-with-Congenital-Hyperinsulinism--Results-thumb

Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients

Rezolute-profiled-in-Nature-thumb

Rezolute profiled in Nature’s BioPharma Dealmakers, Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 editions

Attenuation-of-Insulin-Action-by-an-Allosteric-Insulin-Receptor-Antibody-in-Healthy-Volunteers-thumb

Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers

The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028

XOMA-358,-a-Novel-Treatment-for-Hyperinsulinemic-Hypoglycemia--Safety-and-Clinical-Pharmacology-from-the-First-in-Human-Trial-thumb

XOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial

ENDO 2015 Annual Meeting

Inhibition-of-insulin-receptor-function-by-a-human,-allosteric-monoclonal-antibody--A-potential-new-approach-for-the-treatment-of-hyperinsulinemic-hypoglycemia-thumb

Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: A potential new approach for the treatment of hyperinsulinemic hypoglycemia

mAbs 6:1, 262–272; January/February 2014; © 2014 Landes Bioscience